Abstract 5063
Background
With this study, we aimed to present the impact of malnutrition on the tolerability and efficacy ofchemotheraphy, and overall survival on metastatic gastric cancer (mGC) patients.
Methods
In this prospective multicenter study, we collected demographic, oncological and nutritional data for our mGC patients. Nutritional status was assessed with the Nutritional Risk Index (NRI), Body Mass Index (BMI) and clinical weight loss percentage with 21-day period during two chemotherapy cycles. NRI were calculated with formula as following; 1.519 x serum albumin level (g/L) + 41.7 x current weight/basic weight. Patients were calssified as having ‘no’ (NRI >97.5), ‘moderate’ (97.5 ≥ NRI ≥83.5) or ‘severe’ (NRI <83.5) malnutrition. Drug-induced toxicities were evaluated using National Cancer Institute CTCAE version 4.0 and treatment responses were evaluated using RECIST Criteria 1.1.
Results
116 mGC patients enrolled. Median age was 60 years. Primary location of tumor was non-antrum/antrum with 60/40% and 24% of patients had experienced primary tumor resection. WHO performance status of patients was 0-1 for 98%. All treatments were first-line setting. 41% of patients dead of during follow up period (Median: 138 days, Range: 21-378). Malnurition diagnosed in 68 % of the patients and was severe in 32%. Moderate/severe malnutrution was associated with more treatment toxicity (≥ grade 2 cytopenia, nausea/vomiting, diarrhea, neuropathy; p < 0.05 for all parameters). Moderate/severe malnutrution was not associated with chemoteraphy responses (p = 0.215). Malnutritional level was associated with significantly reduced overall survival (OS), none, moderately or severe malnourished groups, with 350 days (95% CI, 176.0 - 524.0), 210 (95 %CI, 166.3 - 253.7), 74 (95% CI, 20.7 - 111.0) respectively (p = 0.025). Severe malnutition was associated with shorter OS (74 vs. 237 days in non/moderatery, p = 0.007).
Conclusions
In mGC patients, moderate/severe malnutrition is associated with worse non-hematological chemotherapy toxicities. Malnutrition level and severe malnutrition is also associated reduced overall survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3773 - Impact of centralisation of national cancer services on patient outcomes for hepatobiliary cancers in Ireland 2000 – 2016
Presenter: David O Reilly
Session: Poster Display session 2
Resources:
Abstract
3180 - Genomic analysis of hepatobiliary lithiasis associated cholangiocarcinoma revealed a distinct subtype feature.
Presenter: Lunda Gu
Session: Poster Display session 2
Resources:
Abstract
4891 - Comparison of the impact of stereotactic body radiation therapy vs. radiofrequency ablation on liver function in patients with single hepatocellular carcinoma: A propensity score matching analysis
Presenter: Masayuki Ueno
Session: Poster Display session 2
Resources:
Abstract
3203 - Exploratory analysis based on tumor location and early metabolic tumor response of REACHIN, a randomized double-blinded placebo-controlled phase II trial of regorafenib after failure of gemcitabine/platinum-based chemotherapy for advanced and metastatic biliary tract tumors.
Presenter: Anne Demols
Session: Poster Display session 2
Resources:
Abstract
1602 - Predictive Value of Neutrophil-Lymphocyte Ratio (NLR) And Platelet-Lymphocyte Ratio (PLR) In Hepatocellular Carcinoma (HCC) Patients Treated with Nivolumab (N)
Presenter: Sirish Dharmapuri
Session: Poster Display session 2
Resources:
Abstract
2848 - Preliminary Safety and Pharmacokinetics of a New Lysosomotropic Oral Agent, GNS561, in a First-in-Human Study in Advanced Primary Liver Cancer Patients
Presenter: Ahmad Awada
Session: Poster Display session 2
Resources:
Abstract
1396 - A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): updated results
Presenter: Josep Llovet
Session: Poster Display session 2
Resources:
Abstract
1139 - Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in HCC patients treated with sorafenib: Final results of INNOVATE study
Presenter: Andrea Casadei-gardini
Session: Poster Display session 2
Resources:
Abstract
4688 - Prognostic and predictive factors from the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Tim Meyer
Session: Poster Display session 2
Resources:
Abstract
1492 - A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL.
Presenter: David Pinato
Session: Poster Display session 2
Resources:
Abstract